Chemokine receptor-specific antibodies in cancer immunotherapy: Achievements and challenges

Autores
Vela, Maria; Aris, Mariana; Llorente, Mercedes; Garcia Sanz, Jose A.; Kremer, Leonor
Año de publicación
2015
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
The 1990s brought a burst of information regarding the structure, expression pattern, and role in leukocyte migration and adhesion of chemokines and their receptors. At that time, the FDA approved the first therapeutic antibodies for cancer treatment. A few years later, it was reported that the chemokine receptors CXCR4 and CCR7 were involved on directing metastases to liver, lung, bone marrow, or lymph nodes, and the over-expression of CCR4, CCR6, and CCR9 by certain tumors. The possibility of inhibiting the interaction of chemokine receptors present on the surface of tumor cells with their ligands emerged as a new therapeutic approach. Therefore, many research groups and companies began to develop small molecule antagonists and specific antibodies, aiming to neutralize signaling from these receptors. Despite great expectations, so far, only one anti-chemokine receptor antibody has been approved for its clinical use, mogamulizumab, an anti-CCR4 antibody, granted in Japan to treat refractory adult T-cell leukemia and lymphoma. Here, we review the main achievements obtained with anti-chemokine receptor antibodies for cancer immunotherapy, including discovery and clinical studies, proposed mechanisms of action, and therapeutic applications.
Fil: Vela, Maria. Consejo Superior de Investigaciones Científicas. Centro Nacional de Biotecnología; España
Fil: Aris, Mariana. Fundación Cancer; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Llorente, Mercedes. Consejo Superior de Investigaciones Científicas. Centro Nacional de Biotecnología; España
Fil: Garcia Sanz, Jose A.. Consejo Superior de Investigaciones Científicas. Centro Nacional de Biotecnología; España
Fil: Kremer, Leonor. Consejo Superior de Investigaciones Científicas. Centro Nacional de Biotecnología; España
Materia
CANCER
CHEMOKINE RECEPTORS
CLINICAL TRIALS
IMMUNOTHERAPY
THERAPEUTIC ANTIBODIES
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/51004
Acceder
id CONICETDig_35d74dc632c5f6519134d1e7b51b83dd
oai_identifier_str oai:ri.conicet.gov.ar:11336/51004
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Chemokine receptor-specific antibodies in cancer immunotherapy: Achievements and challengesVela, MariaAris, MarianaLlorente, MercedesGarcia Sanz, Jose A.Kremer, LeonorCANCERCHEMOKINE RECEPTORSCLINICAL TRIALSIMMUNOTHERAPYTHERAPEUTIC ANTIBODIEShttps://purl.org/becyt/ford/3.1https://purl.org/becyt/ford/3The 1990s brought a burst of information regarding the structure, expression pattern, and role in leukocyte migration and adhesion of chemokines and their receptors. At that time, the FDA approved the first therapeutic antibodies for cancer treatment. A few years later, it was reported that the chemokine receptors CXCR4 and CCR7 were involved on directing metastases to liver, lung, bone marrow, or lymph nodes, and the over-expression of CCR4, CCR6, and CCR9 by certain tumors. The possibility of inhibiting the interaction of chemokine receptors present on the surface of tumor cells with their ligands emerged as a new therapeutic approach. Therefore, many research groups and companies began to develop small molecule antagonists and specific antibodies, aiming to neutralize signaling from these receptors. Despite great expectations, so far, only one anti-chemokine receptor antibody has been approved for its clinical use, mogamulizumab, an anti-CCR4 antibody, granted in Japan to treat refractory adult T-cell leukemia and lymphoma. Here, we review the main achievements obtained with anti-chemokine receptor antibodies for cancer immunotherapy, including discovery and clinical studies, proposed mechanisms of action, and therapeutic applications.Fil: Vela, Maria. Consejo Superior de Investigaciones Científicas. Centro Nacional de Biotecnología; EspañaFil: Aris, Mariana. Fundación Cancer; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Llorente, Mercedes. Consejo Superior de Investigaciones Científicas. Centro Nacional de Biotecnología; EspañaFil: Garcia Sanz, Jose A.. Consejo Superior de Investigaciones Científicas. Centro Nacional de Biotecnología; EspañaFil: Kremer, Leonor. Consejo Superior de Investigaciones Científicas. Centro Nacional de Biotecnología; EspañaFrontiers Research Foundation2015-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/51004Vela, Maria; Aris, Mariana; Llorente, Mercedes; Garcia Sanz, Jose A.; Kremer, Leonor; Chemokine receptor-specific antibodies in cancer immunotherapy: Achievements and challenges; Frontiers Research Foundation; Frontiers in Immunology; 6; JAN; 1-2015; 1-151664-3224CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/doi/10.3389/fimmu.2015.00012info:eu-repo/semantics/altIdentifier/url/https://www.frontiersin.org/articles/10.3389/fimmu.2015.00012/fullinfo:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-10-15T14:35:48Zoai:ri.conicet.gov.ar:11336/51004instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-10-15 14:35:49.12CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Chemokine receptor-specific antibodies in cancer immunotherapy: Achievements and challenges
title Chemokine receptor-specific antibodies in cancer immunotherapy: Achievements and challenges
spellingShingle Chemokine receptor-specific antibodies in cancer immunotherapy: Achievements and challenges
Vela, Maria
CANCER
CHEMOKINE RECEPTORS
CLINICAL TRIALS
IMMUNOTHERAPY
THERAPEUTIC ANTIBODIES
title_short Chemokine receptor-specific antibodies in cancer immunotherapy: Achievements and challenges
title_full Chemokine receptor-specific antibodies in cancer immunotherapy: Achievements and challenges
title_fullStr Chemokine receptor-specific antibodies in cancer immunotherapy: Achievements and challenges
title_full_unstemmed Chemokine receptor-specific antibodies in cancer immunotherapy: Achievements and challenges
title_sort Chemokine receptor-specific antibodies in cancer immunotherapy: Achievements and challenges
dc.creator.none.fl_str_mv Vela, Maria
Aris, Mariana
Llorente, Mercedes
Garcia Sanz, Jose A.
Kremer, Leonor
author Vela, Maria
author_facet Vela, Maria
Aris, Mariana
Llorente, Mercedes
Garcia Sanz, Jose A.
Kremer, Leonor
author_role author
author2 Aris, Mariana
Llorente, Mercedes
Garcia Sanz, Jose A.
Kremer, Leonor
author2_role author
author
author
author
dc.subject.none.fl_str_mv CANCER
CHEMOKINE RECEPTORS
CLINICAL TRIALS
IMMUNOTHERAPY
THERAPEUTIC ANTIBODIES
topic CANCER
CHEMOKINE RECEPTORS
CLINICAL TRIALS
IMMUNOTHERAPY
THERAPEUTIC ANTIBODIES
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.1
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv The 1990s brought a burst of information regarding the structure, expression pattern, and role in leukocyte migration and adhesion of chemokines and their receptors. At that time, the FDA approved the first therapeutic antibodies for cancer treatment. A few years later, it was reported that the chemokine receptors CXCR4 and CCR7 were involved on directing metastases to liver, lung, bone marrow, or lymph nodes, and the over-expression of CCR4, CCR6, and CCR9 by certain tumors. The possibility of inhibiting the interaction of chemokine receptors present on the surface of tumor cells with their ligands emerged as a new therapeutic approach. Therefore, many research groups and companies began to develop small molecule antagonists and specific antibodies, aiming to neutralize signaling from these receptors. Despite great expectations, so far, only one anti-chemokine receptor antibody has been approved for its clinical use, mogamulizumab, an anti-CCR4 antibody, granted in Japan to treat refractory adult T-cell leukemia and lymphoma. Here, we review the main achievements obtained with anti-chemokine receptor antibodies for cancer immunotherapy, including discovery and clinical studies, proposed mechanisms of action, and therapeutic applications.
Fil: Vela, Maria. Consejo Superior de Investigaciones Científicas. Centro Nacional de Biotecnología; España
Fil: Aris, Mariana. Fundación Cancer; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Llorente, Mercedes. Consejo Superior de Investigaciones Científicas. Centro Nacional de Biotecnología; España
Fil: Garcia Sanz, Jose A.. Consejo Superior de Investigaciones Científicas. Centro Nacional de Biotecnología; España
Fil: Kremer, Leonor. Consejo Superior de Investigaciones Científicas. Centro Nacional de Biotecnología; España
description The 1990s brought a burst of information regarding the structure, expression pattern, and role in leukocyte migration and adhesion of chemokines and their receptors. At that time, the FDA approved the first therapeutic antibodies for cancer treatment. A few years later, it was reported that the chemokine receptors CXCR4 and CCR7 were involved on directing metastases to liver, lung, bone marrow, or lymph nodes, and the over-expression of CCR4, CCR6, and CCR9 by certain tumors. The possibility of inhibiting the interaction of chemokine receptors present on the surface of tumor cells with their ligands emerged as a new therapeutic approach. Therefore, many research groups and companies began to develop small molecule antagonists and specific antibodies, aiming to neutralize signaling from these receptors. Despite great expectations, so far, only one anti-chemokine receptor antibody has been approved for its clinical use, mogamulizumab, an anti-CCR4 antibody, granted in Japan to treat refractory adult T-cell leukemia and lymphoma. Here, we review the main achievements obtained with anti-chemokine receptor antibodies for cancer immunotherapy, including discovery and clinical studies, proposed mechanisms of action, and therapeutic applications.
publishDate 2015
dc.date.none.fl_str_mv 2015-01
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/51004
Vela, Maria; Aris, Mariana; Llorente, Mercedes; Garcia Sanz, Jose A.; Kremer, Leonor; Chemokine receptor-specific antibodies in cancer immunotherapy: Achievements and challenges; Frontiers Research Foundation; Frontiers in Immunology; 6; JAN; 1-2015; 1-15
1664-3224
CONICET Digital
CONICET
url http://hdl.handle.net/11336/51004
identifier_str_mv Vela, Maria; Aris, Mariana; Llorente, Mercedes; Garcia Sanz, Jose A.; Kremer, Leonor; Chemokine receptor-specific antibodies in cancer immunotherapy: Achievements and challenges; Frontiers Research Foundation; Frontiers in Immunology; 6; JAN; 1-2015; 1-15
1664-3224
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/doi/10.3389/fimmu.2015.00012
info:eu-repo/semantics/altIdentifier/url/https://www.frontiersin.org/articles/10.3389/fimmu.2015.00012/full
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Frontiers Research Foundation
publisher.none.fl_str_mv Frontiers Research Foundation
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1846082820390256640
score 13.22299

Publicaciones similares